SCHEMBL1961748

SCHEMBL1961748

COC(=O)c1cnc(NC(C)=O)c(C#C[Si](C)(C)C)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATM Q13315 1/20 0.40
CSF1R P07333 1/20 0.38
MAPK1 P28482 4/20 0.37
ALDH1A1 P00352 2/20 0.36
POLB P06746 2/20 0.36
MAPT P10636 2/20 0.36
PDGFRB P09619 1/20 0.36
KDR P35968 1/20 0.36
KDM4E B2RXH2 4/20 0.35
L3MBTL1 Q9Y468 3/20 0.35
PSMD14 O00487 1/20 0.35
PIK3CA P42336 1/20 0.34
PIK3CB P42338 1/20 0.34
PIK3CG P48736 1/20 0.34
PI4KB Q9UBF8 1/20 0.34
LMNA P02545 1/20 0.34
GAA P10253 1/20 0.34
NFKB1 P19838 1/20 0.34
XDH P47989 1/20 0.34
GFER P55789 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14851276 0.81 ATM (0.44) ATMCSF1RMAPK1ALDH1A1POLB
SCHEMBL1516634 0.80 DYRK1A (0.36) ALDH1A1MAPTKDM4EL3MBTL1LMNA
SCHEMBL1960139 0.80 CSF1R (0.52) ATMCSF1RMAPK1ALDH1A1MAPT
SCHEMBL4770176 0.75 GAA (0.47) ALDH1A1KDM4ELMNAGAATDP1
SCHEMBL14212448 0.75 PDGFRB (0.45) ATMMAPK1ALDH1A1POLBMAPT
SCHEMBL4771954 0.74 GAA (0.43) MAPK1ALDH1A1MAPTKDM4ELMNA
SCHEMBL28852939 0.71 KDM4E (0.44) ATMALDH1A1POLBMAPTKDM4E
SCHEMBL28182939 0.71 KDM4E (0.47) ATMALDH1A1POLBMAPTKDM4E
SCHEMBL21753267 0.71 ATM (0.40) ATMMAPK1ALDH1A1POLBMAPT
SCHEMBL11296185 0.71 CSF1R (0.46) ATMCSF1RMAPK1ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102686587-B Azaindole glucokinase activators HOFFMANN LA ROCHE 2015-05-27 CN disclosed
EP-2513103-A1 AZAINDOLE GLUCOKINASE ACTIVATORS F. Hoffmann-La Roche AG (CH) 2012-10-24 EP disclosed
US-8222416-B2 Azaindole glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2012-07-17 US disclosed
WO-2011073117-A1 AZAINDOLE GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2011-06-23 WO disclosed
US-20110144105-A1 AZAINDOLE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2011-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110144105-A1 AZAINDOLE GLUCOKINASE ACTIVATORS GCK, GCKR, GALK1 ATM 2047/4885CSF1R 4213/4885MAPK1 1342/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.